(Measles + rubella) vaccine is under clinical development by Vaxxas and currently in Phase I for Measles. According to GlobalData, Phase I drugs for Measles have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Measles + rubella) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Measles + rubella) vaccine overview
Vaccine is under development for the prevention of measles and rubella. It is administered through intradermal route as patch. The vaccine is being developed based on high density microneedle array patch (HD-MAP) technology.
Vaxxas develops a microneedle array patch based on its proprietary less invasive vaccine delivery technology platform Nanopatch, that creates potent immune response by applying a patch to the skin for few seconds. The company has operations in Sydney, Australia. Vaxxas is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of (Measles + rubella) vaccine’s drug-specific PTSR and LoA scores, buy the report here.